Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topotecan in combination chemotherapy

E K Rowinsky1, S H Kaufmann

  • 1Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA.

Seminars in Oncology
|January 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

British journal of cancer·2011
Same author

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

British journal of cancer·2011
Same author

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Combination chemotherapy using topotecan shows promise for various cancers, with myelosuppression as a key toxicity. Further trials are needed to optimize dosing and sequencing for improved efficacy and safety.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Chemotherapy

Background:

  • Topotecan is a topoisomerase I inhibitor with demonstrated antitumor activity.
  • Combination chemotherapy regimens are being evaluated for enhanced efficacy.
  • Previous studies explored topotecan with various agents in solid tumors and leukemia.

Purpose of the Study:

  • To evaluate the safety and efficacy of combination chemotherapy regimens containing topotecan.
  • To assess the toxicologic and antineoplastic effects of topotecan in combination with other agents.
  • To address critical issues related to optimal drug dosing and sequencing.

Main Methods:

  • Phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide in adult and pediatric patients.

Related Experiment Videos

  • Studies of topotecan combined with cytarabine, cyclophosphamide, and carboplatin in patients with refractory leukemia.
  • Preclinical and phase I studies examining sequence dependence of toxicologic and antineoplastic effects.

    • Main Results:

    • Myelosuppression, primarily neutropenia, identified as the principal dose-limiting toxicity.
    • Major anti-tumor responses observed in numerous early studies.
    • Sequence dependence of toxicologic and antineoplastic effects noted, particularly with alkylating agents and topoisomerase II inhibitors.

    Conclusions:

    • Combination chemotherapy with topotecan demonstrates significant antitumor activity.
    • Myelosuppression is a critical toxicity requiring careful management.
    • Further phase I and II trials are necessary to optimize topotecan combination therapy regarding dosing and sequencing for improved outcomes.